Clinical Trials
2 trialsNCT07322783 2026-01-07
Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification
Qingdao Central Hospital
Phase 2 Recruiting
NCT04001777 2025-10-01
A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients
Ascentage Pharma Group Inc.
Phase 1 Active not recruiting